Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048126 | 0.85 | ALDH1A1 (0.53) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL13772148 | 0.85 | ALDH1A1 (0.53) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL10500589 | 0.85 | CHRM2 (0.52) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL11913658 | 0.83 | ALDH1A1 (0.52) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL12830800 | 0.79 | CHRM2 (0.59) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL26695363 | 0.75 | FUCA1 (0.50) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL20483452 | 0.74 | CHRM2 (0.64) | CHRM2CHRM4CHRM5SIGMAR1HRH3 | |
| SCHEMBL12564459 | 0.73 | CHRM2 (0.44) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL12564458 | 0.73 | CHRM2 (0.44) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL13813857 | 0.73 | CHRM2 (0.49) | CHRM2CHRM4CHRM5SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| EP-3267996-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144846-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-8609659-B2 | Substituted 3,8-diazabicyclo[3.2.1]octane compounds | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2013-12-17 | — | — | US | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2338889-A1 | Diazacyclic compounds having affinity for opioid receptors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | CHRM2 4808/4885CHRM4 4316/4885CHRM5 4756/4885 |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | CHRM2 40/4885CHRM4 36/4885CHRM5 85/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | CHRM2 4561/4885CHRM4 4713/4885CHRM5 4714/4885 |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | CHRM2 4808/4885CHRM4 4316/4885CHRM5 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.